ClinicalTrials.gg

Program

Oxycodone

Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.

Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.

Furthest: phase 4, since Mar 8, 201164 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mundipharma200 open or runningphase 4since Mar 8, 2011Jul 27, 2007none ahead
Knoa Pharma120 open or runningphase 3since Apr 6, 2006Apr 6, 2006none ahead
Pain Therapeutics120 open or runningphase 3since Mar 13, 2012Aug 12, 2008none ahead
Pfizer60 open or runningphase 4since Jun 8, 2007Jun 8, 2007none ahead
Egalet30 open or runningphase 3since Nov 10, 2015Dec 2, 2008none ahead
Keenova Therapeutics30 open or runningphase 1since Feb 26, 2009Feb 26, 2009none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
biodelivery-sciences-international10 open or runningphase 1since Jun 21, 2019Jun 21, 2019none ahead
elite-laboratories-inc10 open or runningphase 3since Feb 17, 2015Feb 17, 2015none ahead
gl-pharm-tech-corporation10 open or runningphase 1since Mar 19, 2012Mar 19, 2012none ahead
Indivior Pharmaceuticals10 open or runningphase 1since Nov 16, 2018Nov 16, 2018none ahead
napp-pharmaceuticals-limited10 open or runningphase 4since Nov 3, 2008Nov 3, 2008none ahead
vistapharm-inc10 open or runningphase 4since Jul 3, 2013Jul 3, 2013none ahead

Also a collaborator on its studies: pra-health-sciences and Grünenthal.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Feb 20, 2008.

  1. Feb 7, 2014Phase 1 study in HealthyPain Therapeutics · NCT02059915 · 134 enrolled · United States
  2. Mar 13, 2014Phase 1 study in HealthyPain Therapeutics · NCT02089295 · 18 enrolled · United States
  3. Apr 16, 2014Phase 1 study in HealthyPain Therapeutics · NCT02117583 · 34 enrolled · United States
  4. Jun 10, 2014Phase 1 study in HealthyPain Therapeutics · NCT02165930 · 17 enrolled · United States
  5. Oct 13, 2014Phase 3 study in Bronchiolitis Obliterans SyndromeMundipharma · NCT02321397 · 155 enrolled · Germany
  6. Feb 17, 2015elite-laboratories-inc's first study: phase 3 study in Substance Withdrawal SyndromeNew to elite-laboratories-incelite-laboratories-inc · NCT02391571 · 26 enrolled · United States
  7. Nov 10, 2015Phase 3 study in Chronic PainEgalet · NCT02603705 · 281 enrolled · United States
  8. Jan 18, 2016Phase 4 study in Cancer PainMundipharma · NCT02660229 · 66 enrolled · Korea, Republic of
  9. Mar 8, 2016Phase 3 study in Moderate-to-severe Chronic Low Back PainEgalet · NCT02716857 · 549 enrolled · United States
  10. May 22, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176121 · 73 enrolled · Taiwan
  11. Jun 1, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176199 · 30 enrolled · Taiwan
  12. Mar 7, 2018Phase 1 study in Opioid Abuse NondependentPain Therapeutics · NCT03475862 · 38 enrolled · United States
  13. Nov 16, 2018Indivior Pharmaceuticals's first study: phase 1 study in HealthyNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03747341 · 22 enrolled · Netherlands
  14. Jun 21, 2019biodelivery-sciences-international's first study: phase 1 study in Respiratory InsufficiencyNew to biodelivery-sciences-internationalbiodelivery-sciences-international · NCT03996694 · 19 enrolled · United States

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
MethadoneruleMerckphase 416
cebranopadolruleTris Pharmaphase 318
axelopranruleglycyx-therapeuticsphase 28
AlfentanilruleSichuan Kelun Pharmaceuticalphase 11

Studies

The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT03996694Respiratory Insufficiency · United States1Completedbiodelivery-sciences-internationalOct 27, 201919
NCT03747341Healthy · Netherlands1CompletedIndivior PharmaceuticalsJan 4, 201922
NCT03475862Opioid Abuse Nondependent · United States1CompletedPain TherapeuticsJul 31, 201738
NCT03176199Neoplasms · Taiwan4CompletedMundipharmaDec 31, 201830
NCT03176121Neoplasms · Taiwan4CompletedMundipharmaDec 31, 201873
NCT02716857Moderate-to-severe Chronic Low Back Pain · United States3CompletedEgaletAug 2017549
NCT02660229Cancer Pain · Korea, Republic of4CompletedMundipharmaJul 201666
NCT02603705Chronic Pain · United States3CompletedEgaletJun 15, 2017281
NCT02391571Substance Withdrawal Syndrome · United States3Completedelite-laboratories-incMar 201526
NCT02321397Bronchiolitis Obliterans Syndrome · Germany3CompletedMundipharmaMar 2016155
NCT02165930Healthy · United States1CompletedPain TherapeuticsAug 201417
NCT02117583Healthy · United States1CompletedPain TherapeuticsAug 201434
NCT02089295Healthy · United States1CompletedPain TherapeuticsJun 201418
NCT02059915Healthy · United States1CompletedPain TherapeuticsJul 2014134
NCT01986283Substance-Related Disorders · United States1CompletedPain TherapeuticsAug 201467
NCT01924676Healthy · United States1CompletedPain TherapeuticsOct 201318
NCT01918098Non Cancer Pain · China3CompletedMundipharmaMar 30, 2017230
NCT01959204Pain · United States4Completedvistapharm-incAug 21, 201997
NCT01885182Neoplasms · China3CompletedMundipharmaAug 30, 2015232
NCT01825447Healthy · United States1CompletedPfizerSep 201389
NCT01811186Chronic Pain · Korea, Republic of4CompletedMundipharmaJan 2014261
NCT01717027Healthy · United States1CompletedPain TherapeuticsJan 201319
NCT01811238Spinal Disorders4CompletedMundipharmaApr 2013240
NCT01719757Neoplasms · Korea, Republic of4CompletedMundipharmaOct 2013359
NCT01675635Pain, Postoperative3CompletedMundipharmaJun 2012240
NCT01675622Neoplasms3CompletedMundipharmaJun 2012242
NCT01568450Healthy · Korea, Republic of1Completedgl-pharm-tech-corporationApr 201224
NCT01557257Management of Moderate to Severe Pain · United States1CompletedPfizerMay 201213
NCT01559701Pain3CompletedPain TherapeuticsFeb 2008823
NCT01552863Pain · United States1CompletedPain TherapeuticsSep 201221
NCT01552850Pain · Singapore1CompletedPain TherapeuticsJun 201218
NCT01530542Agnosia · United States1CompletedPfizerSep 201035
NCT01643772Pain · China1CompletedMundipharmaJul 201261
NCT01482936Pain · China1CompletedMundipharmaApr 201144
NCT01439100Parkinson Disease · Czech Republic, Germany, Hungary and more3CompletedMundipharmaAug 2013172
NCT01428583Chronic Noncancer Pain · United States3CompletedPfizerMay 2012395
NCT01438567Pain · United Kingdom3CompletedMundipharmaFeb 2014270
NCT01369615Pain · United States, Israel3CompletedKnoa PharmaDec 201323
NCT01313780Neoplasms · Korea, Republic of4CompletedMundipharmaOct 2013128
NCT01304134Other Acute Postoperative Pain · China3CompletedMundipharmaAug 2010240
NCT01192295Pain · United States, Greece, Hungary and more3CompletedKnoa PharmaJul 2014155
NCT01167699Pain · Belgium3CompletedMundipharmaApr 2011174
NCT01101321Healthy · United States1CompletedKnoa PharmaAug 200858
NCT01101308Healthy · United States1CompletedKnoa PharmaAug 200855
NCT01101191Healthy · United States1CompletedKnoa PharmaOct 200784
NCT01101178Healthy · United States1CompletedKnoa PharmaNov 200779
NCT01101165Healthy · United States1CompletedKnoa PharmaApr 200792
NCT01100320Healthy Volunteers · United States1CompletedKnoa PharmaMar 200788
NCT01100086Healthy Volunteers · United States1CompletedKnoa PharmaMar 200784
NCT01099709Healthy Volunteers · United States1CompletedKnoa PharmaMar 200785
NCT00864526Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200640
NCT00864357Healthy · United States1CompletedTeva Pharmaceutical IndustriesOct 200640
NCT00853736Healthy · United States1CompletedKeenova TherapeuticsFeb 200323
NCT00853320Healthy · United States1CompletedKeenova TherapeuticsFeb 200338
NCT00853216Healthy · United States1CompletedKeenova TherapeuticsFeb 200338
NCT00801788Pain · Canada1CompletedEgaletOct 200816
NCT00784810Osteoarthritis · United Kingdom4Completednapp-pharmaceuticals-limitedMar 2010247
NCT00743587Osteoarthritis Thumbs · Belgium1CompletedPfizerMar 200936
NCT00734461Opioid-Related Disorders · United States2CompletedPain TherapeuticsMar 200914
NCT00626600Cancer Pain · United Kingdom3TerminatedMundipharmaMay 200933

How it is read

Names in the registry

  • “Oxycodone”, 43 entries
  • “Reformulated OXY (oxycodone HCl)”, 6 entries
  • “Oxycodone/Naloxone”, 5 entries
  • “oxycodone hydrochloride”, 4 entries
  • “Oxycodone hydrochloride”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.